If You Invested in Applied DNA Sciences, Inc. (APDN)

Applied DNA Sciences, Inc. (NASDAQ: APDN), now renamed BNB Plus Corp. with the trading symbol BNBX on the Nasdaq Stock Market, is a biotechnology company that has combined a long history in polymerase chain reaction (PCR)-based DNA technologies with a newly adopted digital asset treasury strategy centered on BNB, the native cryptocurrency of the Binance blockchain ecosystem.

Prior to the launch of its BNB-focused treasury strategy, the company described itself as a biotechnology business focused on providing nucleic acid production solutions for the biopharmaceutical and diagnostics industries. Using PCR to enable both the production and detection of deoxyribonucleic acid (DNA), the company has operated in markets that include the enzymatic manufacture of synthetic DNA for use in nucleic acid-based therapeutics and the development and sale of a proprietary RNA polymerase (RNAP) for use in the production of messenger RNA (mRNA) therapeutics, as well as the detection of DNA and RNA in molecular diagnostics and genetic testing services.

Business focus and technology platforms

According to multiple company disclosures, Applied DNA Sciences has over two decades of experience in developing and commercializing PCR-based applications for DNA production. Through its majority-owned subsidiary LineaRx, Inc., the company has been commercializing several key platforms intended to support the manufacture of next-generation nucleic acid-based therapies:

• LineaDNA™: A proprietary, cell-free DNA production system that uses large-scale PCR to produce high-fidelity synthetic DNA. Company materials state that the platform can generate DNA from 100 base pairs to 20 kilobases in quantities from milligrams to grams under various quality grades. The DNA is described as free of adventitious sequences, rapidly scalable, and amenable to chemical modification, and is positioned as an alternative to plasmid DNA for biotherapeutics development and production, as starting material for mRNA therapeutics and vaccines, and as a functional component in in vitro diagnostics (IVDs).
• LineaRNAP™: A next-generation T7 RNA polymerase used to transcribe DNA into mRNA. The company reports that LineaRNAP incorporates a patented DNA-binding domain that it believes delivers high mRNA yields while reducing double-stranded RNA (dsRNA) contamination, a common byproduct in mRNA production. LineaRNAP is marketed both as a standalone product and as part of an integrated workflow.
• LineaIVT™: An integrated platform that combines LineaDNA and LineaRNAP technologies. Company descriptions state that this system is designed to streamline mRNA production by bypassing plasmid DNA as a starting material, reducing dsRNA contamination, and simplifying mRNA production workflows.

In its financial and operational updates, the company has described a strategic transition to a “pure play” provider of synthetic DNA and mRNA manufacturing solutions for advanced biotherapeutics, such as gene therapies, personalized medicine, adoptive cell therapies, mRNA therapeutics, DNA vaccines, and diagnostic applications that utilize chemically modified DNA. This transition has included the wind down of its DNA Tagging and Security Products and Services segment and the closure of its Applied DNA Clinical Labs (ADCL) molecular and genetic testing services business, with operations consolidated behind LineaRx.

BNB-focused digital asset treasury strategy

In later disclosures, Applied DNA Sciences announced a significant strategic shift: the initiation of a BNB-focused digital asset treasury strategy and the planned change of its Nasdaq ticker from APDN to BNBX, followed by a corporate name change to BNB Plus Corp. The company has stated that it intends to use proceeds from a private placement and related offerings to acquire BNB and manage digital assets, primarily BNB, through staking, restaking, liquid staking, and other Binance ecosystem yield opportunities. The stated objective is to optimize yield generation and token accumulation within the Binance ecosystem and to position the treasury as a driver of capital efficiency, liquidity resilience, and exposure to digital asset upside.

To support this strategy, the company has entered into a Strategic Digital Assets Services Agreement with Cypress LLC for discretionary asset management services aligned with its BNB-focused treasury approach, and a Strategic Advisor Agreement with Cypress Management LLC for strategic and technical advisory services relating to crypto-asset operations. The company has also highlighted the involvement of institutional and crypto-native investors in its private placement, and the formation of a crypto strategic advisory board.

Corporate restructuring and operational realignment

Company announcements describe several restructuring actions intended to reduce operating costs and concentrate resources on its synthetic DNA manufacturing business and later on its BNB-focused treasury strategy. These actions have included workforce reductions, the cessation of ADCL operations, and the exit from non-core business segments such as DNA tagging and security products and services. The company has characterized these steps as part of a broader effort to align operations with its highest-conviction growth opportunities and to improve operational efficiency.

Applied DNA Sciences has also reported that it regained compliance with Nasdaq’s minimum bid price requirement, allowing its securities to continue to be listed and traded on the Nasdaq Capital Market. Subsequent filings document the adoption of at-the-market and private placement financing arrangements, reverse stock splits, and proposals to increase authorized shares and equity plan reserves, all of which are described as mechanisms to support capital needs and strategic initiatives.

Industry context and applications

Within biotechnology and nucleic acid manufacturing, the company positions its LineaDNA, LineaRNAP, and LineaIVT platforms for use in the production of DNA- and RNA-based medicines and in vitro diagnostics. Company communications reference applications in areas such as mRNA therapeutics and vaccines, adoptive cell therapies, gene editing, and cancer diagnostics, including follow-on orders from a global IVD manufacturer for LineaDNA used as a functional component of a cancer diagnostic test, and collaborations with mRNA-focused contract development and manufacturing organizations.

In parallel, the company’s BNB-focused treasury strategy places it at the intersection of biotechnology and digital assets. Disclosures state that the company views the BNB ecosystem as a significant growth opportunity in the global digital asset space and intends to integrate actively managed decentralized finance protocols and Binance ecosystem-specific strategies into its treasury management.

APDN ticker and corporate evolution

The ticker symbol APDN historically represented Applied DNA Sciences, Inc., a biotechnology company centered on PCR-based DNA production and detection technologies. In its later phase under the APDN symbol, the company undertook a strategic restructuring to focus on synthetic DNA and mRNA manufacturing platforms and then initiated a BNB-focused digital asset treasury strategy funded through private placements and other capital markets activities. Subsequent filings document the change of the Nasdaq trading symbol from APDN to BNBX and the corporate name change to BNB Plus Corp., reflecting the company’s emphasis on its BNB-based treasury strategy.